Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory
response to hypoglycaemia, with glucagon as the most important mediator, is initially
diminished within a few years of onset of Type 1 diabetes and subsequently lost and thus
increasing the risk of hypoglycaemia. Dipeptidyl Peptidase (DPP)-4 inhibitors augment the
glucagon response to insulin-induced hypoglycaemia in type 2 diabetes. The investigators
hypothesize that treatment with a DPP-4 inhibitor in patients with type 1 diabetes will
recover the alpha cell response to hypoglycaemia.
Phase:
N/A
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate